Evercore ISI Downgrades AN2 Therapeutics (ANTX) to In Line

February 12, 2024 11:38 AM EST Send to a Friend
Evercore ISI analyst Liisa Bayko downgraded AN2 Therapeutics (NASDAQ: ANTX) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login